Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2021
Same author

Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies.

Clinical cancer research : an official journal of the American Association for Cancer Research·2021
Same author

Early detection of pancreatic cancer: current state and future opportunities.

Current opinion in gastroenterology·2021
Same author

PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma.

Nature communications·2021
Same author

Longitudinal assessment of lung clearance index to monitor disease progression in children and adults with cystic fibrosis.

Thorax·2021
Same author

EXO5-DNA structure and BLM interactions direct DNA resection critical for ATR-dependent replication restart.

Molecular cell·2021

Related Experiment Video

Updated: Mar 27, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.7K

Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer.

Lucas A Mavromatis1, Viktor Zlatanic2, Emil Agarunov2

  • 1Division of Precision Medicine, Department of Medicine, New York University Grossman School of Medicine, New York.

JAMA Oncology
|March 26, 2026
PubMed
Summary

A new model called PRIME, using electronic health records, can predict pancreatic cancer risk. This tool helps identify high-risk individuals for earlier detection and improved outcomes.

More Related Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.6K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1.0K

Related Experiment Videos

Last Updated: Mar 27, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.7K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.6K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1.0K

Area of Science:

  • Oncology
  • Epidemiology
  • Health Informatics

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is a significant cause of cancer mortality in the US.
  • Early detection of PDAC is crucial for improving patient survival rates.
  • Population-wide screening for PDAC is challenging due to its rarity.

Purpose of the Study:

  • To develop and validate the PRIME (PDAC Risk Model for Earlier Detection) model.
  • To predict incident PDAC using readily available electronic health record (EHR) data.
  • To create a parsimonious, interpretable, and generalizable risk prediction model.

Main Methods:

  • A large cohort study utilizing the Optum Labs Data Warehouse, a deidentified US EHR and claims database.
  • Inclusion of adults aged 40 years or older with outpatient encounters between 2016-2018.
  • International validation in the UK Biobank, with data analysis from July 2025 to January 2026.

Main Results:

  • The PRIME model identified 19 key predictors, including history of pancreatitis, GI disorders, prior cancers, type 2 diabetes, elevated AST, smoking, non-type-O blood, and male sex.
  • The model demonstrated strong discrimination at 36 months with an AUC of 0.75 in both training and validation cohorts.
  • Patients in the top 1% of predicted risk showed a 7.63-fold higher risk of PDAC compared to average-risk patients.

Conclusions:

  • The PRIME model, based on EHR data, effectively stratified PDAC risk across diverse US health systems and showed international generalizability.
  • PRIME is a transparent and effective tool for identifying individuals at higher risk for pancreatic cancer.
  • Future research should explore EHR-guided PDAC case-finding and integration with blood-based detection assays.